Related references
Note: Only part of the references are listed.The epidemiology of sexually transmitted infections in the UK: impact of behavior, services and interventions
Gwenda Hughes et al.
FUTURE MICROBIOLOGY (2015)
Impact of quadrivalent human papillomavirus vaccine in women at increased risk of genital warts burden: Population-based cross-sectional survey of Czech women aged 16 to 40 years
Marek Petras et al.
VACCINE (2015)
Improving surveillance of sexually transmitted infections using mandatory electronic clinical reporting: the genitourinary medicine clinic activity dataset, England, 2009 to 2013
E. J. Savage et al.
EUROSURVEILLANCE (2014)
Declining Genital Warts in Young Women in England Associated With HPV 16/18 Vaccination: An Ecological Study
Rebecca Howell-Jones et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
Anne Szarewski et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal)
Catherine H. Mercer et al.
LANCET (2013)
Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata
Matthew G. Hawkins et al.
VIROLOGY JOURNAL (2013)
Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data
Hammad Ali et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Genital warts and cost of care in England
Sarika Desai et al.
SEXUALLY TRANSMITTED INFECTIONS (2011)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
LL Villa et al.
LANCET ONCOLOGY (2005)
Share Paper
